Expertise in
2
conditions

Kaichi Nishiwaki

Kashiwa, JP 
Expertise in
2
conditions
Kashiwa, JP 

Overview

Kaichi Nishiwaki practices practicing medicine in Kashiwa, Japan.

Nishiwaki is highly rated in 2 conditions, according to our data. Their clinical expertise encompasses Chronic Myelogenous Leukemia (CML), Multiple Myeloma, Leukemia, Paroxysmal Cold Hemoglobinuria, and Bone Marrow Transplant.

They are actively involved in clinical research, co-authoring 53 peer reviewed articles and participating in 1 clinical trial.

Locations

Kashiwa, Japan
Other Locations
Minato, 1058461, Japan
Tokyo, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Pom/Dex (Pomalidomide plus Low Dose Dexamethasone)
Study Phase: Phase 3

53 Total Publications

Effect of efgartigimod IV on immature platelet fraction in primary immune thrombocytopenia in the ADVANCE IV trial.
Effect of efgartigimod IV on immature platelet fraction in primary immune thrombocytopenia in the ADVANCE IV trial.
Journal: British journal of haematology
Published: June 10, 2026

Frequently Asked Questions about Kaichi Nishiwaki

Is Kaichi Nishiwaki a top-rated expert for Chronic Myelogenous Leukemia (CML)?

MediFind is an objective health platform that identifies experts based on real-world data. Kaichi Nishiwaki is classified as an Advanced expert for Chronic Myelogenous Leukemia (CML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Kaichi Nishiwaki participate in research or clinical trials?

Yes. Kaichi Nishiwaki has published 53 articles and abstracts on conditions like Chronic Myelogenous Leukemia (CML). You can view a list of Kaichi Nishiwaki's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Nishiwaki's expertise for a condition
ConditionClose
      View All 25 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile